QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Historical Signal Evaluation of SGLT2 Inhibitors and Diabetic Ketoacidosis

Test your understanding of the concepts covered by Historical Signal Evaluation: SGLT2 Inhibitors and Diabetic Ketoacidosis.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement best reflects the article's position on the mechanism of SGLT2 inhibitor-associated DKA?

One single mechanism has been conclusively demonstrated to explain every case The mechanism is biologically plausible but multifactorial, with some pathways incompletely established Mechanistic evidence is irrelevant once spontaneous reports exist The mechanism is disproven because early clinical trials were statistically negative

Question 2 of 10 How should the 2020 estimate of approximately 1.7 additional DKA events per 1,000 patients over five years be used in benefit-risk assessment?

It should be ignored because relative risks are always more informative It indicates that a serious relative increase can coexist with a small absolute excess risk It proves that DKA is too rare to justify any regulatory action It means that one in every 1.7 treated patients will develop DKA

Question 3 of 10 Which clinical presentation should most strongly prompt consideration of DKA in a patient receiving an SGLT2 inhibitor?

Glucose of 160 mg/dL with nausea, tachypnoea, high-anion-gap acidosis and elevated ketones Glucose of 160 mg/dL with no symptoms, normal anion gap and no ketones Mild isolated thirst after exercise with normal acid-base findings Asymptomatic hyperglycaemia without ketonaemia or acidosis

Question 4 of 10 If DKA is suspected or confirmed in a patient taking an SGLT2 inhibitor, what action is most consistent with the described recommendations?

Continue the SGLT2 inhibitor until glucose exceeds a predefined threshold Stop the medicine immediately and do not restart unless another clear cause has been identified and resolved Restart immediately once glucose normalises, regardless of the cause Treat only the glucose value and defer evaluation of ketones

Question 5 of 10 Which statement best explains why the absence of rechallenge evidence should not substantially undermine this signal?

Rechallenge is generally clinically inappropriate after a serious DKA event Rechallenge is mandatory for every serious adverse drug reaction Rechallenge is unnecessary because individual case reports prove causality Rechallenge is routinely performed in patients with life-threatening metabolic reactions

Question 6 of 10 What was the main regulatory outcome of the 2015–2016 European review?

Withdrawal of all SGLT2 inhibitors from the European market Risk minimisation through changes to product information and clinical recommendations A conclusion that DKA was unrelated to the drug class Restriction of all SGLT2 inhibitors exclusively to type 1 diabetes

Question 7 of 10 What is the most appropriate way for a QPPV to use later evidence when reassessing the historical signal?

Retain the original early-trial conclusion permanently Consider only evidence that confirms the original signal Reassess the signal dynamically, incorporating newer randomised, observational and mechanistic evidence while preserving the historical context Replace all clinical evidence with mechanistic hypotheses

Question 8 of 10 Which statement best distinguishes the two central pharmacovigilance concerns raised by this signal?

The drug may increase DKA incidence and may also alter DKA presentation The drug may cause hyperglycaemia and independently prevent metabolic acidosis The drug may increase renal failure and eliminate the need for ketone testing The drug may cause only gastrointestinal symptoms but not metabolic complications

Question 9 of 10 Which statement best captures the regulatory benefit-risk conclusion described in the article?

Any serious adverse reaction requires withdrawal regardless of frequency or benefit The class was withdrawn because the relative risk was doubled The serious but uncommon risk could be addressed through targeted measures while benefits remained favourable for authorised type 2 diabetes use The risk was considered irrelevant because the absolute excess was small

Question 10 of 10 Which regulatory process sequence is correct for the European review described in the article?

CHMP initiated the procedure, followed by PRAC advice and no Commission decision The European Commission initiated an Article 20 procedure, PRAC completed its review, CHMP reviewed it, and the Commission issued the legally binding decision PRAC initiated a criminal enforcement procedure followed by national court review The procedure was initiated by a clinical trial sponsor and concluded by an ethics committee

QPPV.com

Knowledge Assessment: Historical Signal Evaluation of SGLT2 Inhibitors and Diabetic Ketoacidosis

Cookie Settings